Literature DB >> 23911707

Reversion and conversion of interferon-γ release assay results in HIV-1-infected individuals.

Maximilian C Aichelburg1, Thomas Reiberger, Florian Breitenecker, Mattias Mandorfer, Athanasios Makristathis, Armin Rieger.   

Abstract

In this prospective study, human immunodeficiency virus type 1 (HIV-1)-infected subjects underwent QuantiFERON-TB Gold In-Tube interferon-γ release assay (IGRA) testing at baseline and after 24 months in a low tuberculosis incidence country. Concordant baseline and follow-up results were observed in 86% (n = 686 of 794) of subjects. IGRA conversions occurred in 9% (n = 63 of 718), whereas IGRA reversions were seen in 33% (n = 25 of 76) of individuals. Of the 10 active tuberculosis cases during follow-up, 5 had concordant positive IGRA results and 2 were IGRA converters. Although the clinical significance of IGRA conversions and reversions remains to be established, repeated IGRA testing seems to be of value in HIV-1-infected individuals.

Entities:  

Keywords:  conversion; human immunodeficiency virus type 1; interferon-gamma release assay; reversion; serial testing

Mesh：

Substances：

Year:  2013        PMID： 23911707     DOI： 10.1093/infdis/jit418

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  7 in total

1.  Effect of Pregnancy on Interferon Gamma Release Assay and Tuberculin Skin Test Detection of Latent TB Infection Among HIV-Infected Women in a High Burden Setting.

Authors:  Sylvia M LaCourse; Lisa M Cranmer; Daniel Matemo; John Kinuthia; Barbra A Richardson; David J Horne; Grace John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

2.  Incidence and correlates of tuberculosis IGRA conversion among HIV-infected postpartum women.

Authors:  S Jonnalagadda; S M LaCourse; P Otieno; B Lohman-Payne; E Maleche-Obimbo; L M Cranmer; G C John-Stewart
Journal:  Int J Tuberc Lung Dis       Date:  2015-07       Impact factor: 2.373

3.  Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California.

Authors:  S S Shin; A H Chang; J K C Ghosh; M P Dubé; R Bolan; O O Yang; P R Kerndt
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

4.  Paradox of serial interferon-gamma release assays: variability width more important than specificity size.

Authors:  J E Stout; R Belknap; Y-J Wu; C S Ho
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 3.427

5.  QuantiFERON-TB Gold In-Tube test conversions and reversions among tuberculosis patients and their household contacts in Addis Ababa: a one year follow-up study.

Authors:  Mulugeta Belay; Mengistu Legesse; Daniel Dagne; Adane Mihret; Yonas Bekele; Girmay Medhin; Gunnar Bjune; Fekadu Abebe
Journal:  BMC Infect Dis       Date:  2014-12-03       Impact factor: 3.090

6.  HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study.

Authors:  Nadine Durema Pullar; Harald Steinum; Johan Nikolai Bruun; Anne Ma Dyrhol-Riise
Journal:  BMC Infect Dis       Date:  2014-12-17       Impact factor: 3.090

7.  Cytokine Patterns in Tuberculosis Infection; IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from Uninfected Controls.

Authors:  Ida Wergeland; Jörg Assmus; Anne Ma Dyrhol-Riise
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.